Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Optic Disk | 21 | 2024 | 59 | 8.420 |
Why?
|
Retinal Ganglion Cells | 20 | 2024 | 100 | 7.150 |
Why?
|
Tomography, Optical Coherence | 34 | 2024 | 217 | 6.630 |
Why?
|
Intraocular Pressure | 16 | 2024 | 62 | 4.360 |
Why?
|
Glaucoma | 10 | 2024 | 40 | 4.100 |
Why?
|
Nerve Fibers | 15 | 2024 | 56 | 3.690 |
Why?
|
Macaca mulatta | 16 | 2024 | 126 | 3.100 |
Why?
|
Optic Nerve Diseases | 8 | 2024 | 29 | 2.870 |
Why?
|
Disease Models, Animal | 12 | 2024 | 242 | 2.620 |
Why?
|
Visual Fields | 6 | 2024 | 67 | 2.510 |
Why?
|
Papilledema | 10 | 2022 | 14 | 2.140 |
Why?
|
Space Flight | 9 | 2024 | 26 | 2.010 |
Why?
|
Macula Lutea | 5 | 2024 | 17 | 1.810 |
Why?
|
Bruch Membrane | 6 | 2023 | 19 | 1.520 |
Why?
|
Animals | 25 | 2024 | 1817 | 1.490 |
Why?
|
Astronauts | 9 | 2024 | 20 | 1.470 |
Why?
|
Male | 30 | 2024 | 2770 | 1.450 |
Why?
|
Female | 28 | 2024 | 2816 | 1.410 |
Why?
|
Glaucoma, Open-Angle | 3 | 2020 | 9 | 1.270 |
Why?
|
Visual Field Tests | 4 | 2024 | 39 | 1.140 |
Why?
|
Tonometry, Ocular | 5 | 2020 | 39 | 1.100 |
Why?
|
Visual Acuity | 4 | 2024 | 179 | 1.000 |
Why?
|
Weightlessness | 3 | 2024 | 15 | 0.980 |
Why?
|
Head-Down Tilt | 2 | 2023 | 4 | 0.930 |
Why?
|
Humans | 31 | 2024 | 5485 | 0.910 |
Why?
|
Fovea Centralis | 3 | 2024 | 29 | 0.780 |
Why?
|
Circadian Rhythm | 2 | 2019 | 36 | 0.770 |
Why?
|
Choroid | 7 | 2024 | 25 | 0.770 |
Why?
|
Sclera | 2 | 2020 | 57 | 0.750 |
Why?
|
Axial Length, Eye | 6 | 2024 | 25 | 0.750 |
Why?
|
Biometry | 9 | 2020 | 32 | 0.740 |
Why?
|
Middle Aged | 15 | 2024 | 1100 | 0.730 |
Why?
|
Refraction, Ocular | 5 | 2024 | 127 | 0.730 |
Why?
|
Adult | 12 | 2024 | 1687 | 0.710 |
Why?
|
Young Adult | 9 | 2024 | 852 | 0.710 |
Why?
|
Myopia | 5 | 2024 | 114 | 0.660 |
Why?
|
Eye Diseases, Hereditary | 1 | 2019 | 5 | 0.660 |
Why?
|
Ocular Physiological Phenomena | 1 | 2019 | 6 | 0.650 |
Why?
|
Models, Animal | 2 | 2021 | 25 | 0.630 |
Why?
|
Contact Lenses | 1 | 2020 | 71 | 0.630 |
Why?
|
Retina | 6 | 2024 | 130 | 0.630 |
Why?
|
Retinal Vessels | 4 | 2024 | 16 | 0.610 |
Why?
|
Anterior Eye Segment | 3 | 2020 | 12 | 0.600 |
Why?
|
Time Factors | 6 | 2022 | 176 | 0.600 |
Why?
|
Optic Nerve | 3 | 2023 | 9 | 0.520 |
Why?
|
Axons | 2 | 2014 | 18 | 0.480 |
Why?
|
Intracranial Pressure | 4 | 2020 | 6 | 0.470 |
Why?
|
Electroretinography | 4 | 2021 | 57 | 0.420 |
Why?
|
Cell Count | 2 | 2024 | 33 | 0.410 |
Why?
|
Aging | 1 | 2014 | 127 | 0.410 |
Why?
|
Microscopy, Confocal | 2 | 2024 | 49 | 0.400 |
Why?
|
Ocular Hypertension | 4 | 2021 | 11 | 0.390 |
Why?
|
Anterior Chamber | 2 | 2020 | 7 | 0.350 |
Why?
|
Retinal Cone Photoreceptor Cells | 2 | 2021 | 35 | 0.350 |
Why?
|
Emmetropia | 2 | 2018 | 14 | 0.300 |
Why?
|
Adolescent | 3 | 2020 | 806 | 0.290 |
Why?
|
Aged | 4 | 2015 | 860 | 0.270 |
Why?
|
Reference Values | 2 | 2020 | 28 | 0.270 |
Why?
|
Retrospective Studies | 2 | 2019 | 382 | 0.270 |
Why?
|
Capillaries | 3 | 2022 | 8 | 0.270 |
Why?
|
Healthy Volunteers | 3 | 2023 | 42 | 0.270 |
Why?
|
Refractive Errors | 2 | 2024 | 58 | 0.270 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 284 | 0.260 |
Why?
|
ROC Curve | 2 | 2019 | 31 | 0.260 |
Why?
|
Hyperopia | 2 | 2024 | 15 | 0.260 |
Why?
|
Disease Progression | 2 | 2018 | 74 | 0.260 |
Why?
|
Age Factors | 2 | 2017 | 75 | 0.250 |
Why?
|
Fluorescein Angiography | 3 | 2024 | 11 | 0.250 |
Why?
|
Reproducibility of Results | 3 | 2018 | 350 | 0.240 |
Why?
|
Cornea | 2 | 2020 | 140 | 0.230 |
Why?
|
Microvessels | 1 | 2024 | 7 | 0.230 |
Why?
|
Ultrasonography | 2 | 2023 | 21 | 0.230 |
Why?
|
Antibodies, Viral | 1 | 2024 | 14 | 0.230 |
Why?
|
Administration, Intranasal | 1 | 2024 | 11 | 0.230 |
Why?
|
Primates | 1 | 2023 | 8 | 0.210 |
Why?
|
Vision Disorders | 2 | 2024 | 44 | 0.210 |
Why?
|
Trabecular Meshwork | 2 | 2021 | 6 | 0.210 |
Why?
|
Laser Therapy | 2 | 2021 | 8 | 0.210 |
Why?
|
Child | 3 | 2024 | 657 | 0.210 |
Why?
|
Posterior Eye Segment | 2 | 2020 | 3 | 0.200 |
Why?
|
Follow-Up Studies | 2 | 2022 | 97 | 0.190 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2021 | 37 | 0.180 |
Why?
|
Face | 1 | 2021 | 25 | 0.180 |
Why?
|
Optic Nerve Injuries | 1 | 2020 | 6 | 0.180 |
Why?
|
Photic Stimulation | 3 | 2021 | 148 | 0.170 |
Why?
|
Bed Rest | 1 | 2020 | 1 | 0.170 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 18 | 0.160 |
Why?
|
Longitudinal Studies | 2 | 2017 | 148 | 0.160 |
Why?
|
Analysis of Variance | 1 | 2019 | 81 | 0.160 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 135 | 0.160 |
Why?
|
Geniculate Bodies | 1 | 2018 | 3 | 0.160 |
Why?
|
Sensory Deprivation | 1 | 2018 | 8 | 0.160 |
Why?
|
Visual Cortex | 1 | 2018 | 24 | 0.150 |
Why?
|
Child, Preschool | 1 | 2019 | 187 | 0.150 |
Why?
|
Brain | 2 | 2021 | 286 | 0.150 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2018 | 4 | 0.150 |
Why?
|
Xanthines | 1 | 2018 | 3 | 0.150 |
Why?
|
Anisometropia | 1 | 2018 | 7 | 0.150 |
Why?
|
Cohort Studies | 3 | 2022 | 131 | 0.130 |
Why?
|
Optic Atrophy | 1 | 2015 | 1 | 0.120 |
Why?
|
Retinal Vein | 1 | 2015 | 1 | 0.120 |
Why?
|
Retinal Diseases | 1 | 2015 | 13 | 0.120 |
Why?
|
Neuroimaging | 1 | 2015 | 25 | 0.120 |
Why?
|
Functional Laterality | 1 | 2015 | 38 | 0.120 |
Why?
|
Ophthalmoscopes | 3 | 2020 | 11 | 0.110 |
Why?
|
Toll-Like Receptors | 1 | 2013 | 4 | 0.110 |
Why?
|
Dry Eye Syndromes | 1 | 2013 | 12 | 0.100 |
Why?
|
Optics and Photonics | 1 | 2012 | 21 | 0.100 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 77 | 0.100 |
Why?
|
Syndrome | 2 | 2024 | 5 | 0.100 |
Why?
|
Equipment Design | 1 | 2012 | 74 | 0.100 |
Why?
|
Tissue Fixation | 1 | 2011 | 4 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2011 | 21 | 0.090 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2011 | 4 | 0.090 |
Why?
|
Ophthalmoscopy | 2 | 2022 | 10 | 0.090 |
Why?
|
Contact Lenses, Hydrophilic | 1 | 2012 | 78 | 0.090 |
Why?
|
Macaca | 2 | 2021 | 11 | 0.090 |
Why?
|
Mice | 3 | 2024 | 719 | 0.080 |
Why?
|
Lasers | 2 | 2020 | 9 | 0.080 |
Why?
|
Prospective Studies | 2 | 2020 | 132 | 0.070 |
Why?
|
Animals, Newborn | 2 | 2018 | 37 | 0.060 |
Why?
|
Vitamin B 12 | 1 | 2024 | 2 | 0.060 |
Why?
|
Antigens, Viral | 1 | 2024 | 4 | 0.060 |
Why?
|
Mesocricetus | 1 | 2024 | 4 | 0.060 |
Why?
|
Antibodies, Neutralizing | 1 | 2024 | 7 | 0.060 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2024 | 11 | 0.060 |
Why?
|
Mice, Inbred BALB C | 1 | 2024 | 22 | 0.060 |
Why?
|
Cricetinae | 1 | 2024 | 21 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2024 | 26 | 0.060 |
Why?
|
Edema | 1 | 2022 | 1 | 0.050 |
Why?
|
Body Weight | 1 | 2022 | 59 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2013 | 195 | 0.050 |
Why?
|
Nerve Crush | 1 | 2020 | 5 | 0.050 |
Why?
|
Guinea Pigs | 1 | 2020 | 10 | 0.040 |
Why?
|
Perfusion | 1 | 2020 | 9 | 0.040 |
Why?
|
Carbon Dioxide | 1 | 2020 | 9 | 0.040 |
Why?
|
Extraterrestrial Environment | 1 | 2019 | 5 | 0.040 |
Why?
|
Visual Pathways | 1 | 2018 | 19 | 0.040 |
Why?
|
Interferometry | 1 | 2018 | 6 | 0.040 |
Why?
|
Neuronal Plasticity | 1 | 2018 | 21 | 0.040 |
Why?
|
Administration, Oral | 1 | 2018 | 35 | 0.040 |
Why?
|
Image Enhancement | 1 | 2015 | 42 | 0.030 |
Why?
|
Biomarkers | 1 | 2015 | 87 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2015 | 321 | 0.030 |
Why?
|
beta-Defensins | 1 | 2013 | 1 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2013 | 3 | 0.030 |
Why?
|
Cathelicidins | 1 | 2013 | 6 | 0.030 |
Why?
|
Corneal Ulcer | 1 | 2013 | 4 | 0.030 |
Why?
|
DNA Primers | 1 | 2013 | 17 | 0.030 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2013 | 7 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 20 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 250 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2013 | 69 | 0.030 |
Why?
|
Microwaves | 1 | 2011 | 3 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 116 | 0.020 |
Why?
|